Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck pharmaceutical Segment — SG&A Expense ($M) ($M)
Form 10-Q / 10-K Segment Footnote
Latest, Q2 2026
1,437
Period ended Jun 30, 2026
Change on a year earlier
+5.1%
1,367 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pharmaceutical Segment — SG&A Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,437 | +5.1% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,332 | -5.0% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,547 | -7.1% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,469 | -3.3% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,367 | -9.7% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,402 | -1.9% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,666 | – | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,519 | – | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,514 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,429 | – | Form 10-Q (filed 2025-05-02) ↗ |
Cite this data
StockData. (2026). Merck Pharmaceutical Segment — SG&A Expense ($M) ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db_seg_pharma_sga
See every metric in the Merck KPI table. Data updated Oct 26, 2026.